Creating mathematical and computational models of infectious diseases like pandemic flu gives government and policy-makers a toolkit to respond to this ever-present threat.
The World Health Organization (WHO) developed the Global Influenza Strategy for 2019–2030 to enhance global and national pandemic preparedness, to combat the ongoing threat of zoonotic influenza, and to improve seasonal influenza prevention and control in all countries.
The World Health Organization (WHO) has released a Global Influenza Strategy for 2019-2030 aimed at protecting people in all countries from the threat of influenza.
In a move to defeat the next pandemic, the CEPI (Coalition for Epidemic Preparedness Innovations) has reportedly signed an agreement with CureVac, a German biopharmaceutical firm. The duo plan to develop a vaccine printing technology, with an aim to produce shots against various diseases.
Researchers have developed a mathematical framework to estimate the value of investing in developing and conserving an antibiotic to mitigate the burden of bacterial infections caused by resistant Staphylococcus aureus during a pandemic influenza outbreak.
The H5N1 avian influenza antigen and adjuvant maintained their functional integrity in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS), according to testing by the US Biomedical Advanced Research and Development Authority (BARDA).
Health experts should only replenish flu vaccines in areas that need them, researchers argue in a new paper.
A couple years ago, the Zika virus startled the world with its until-then unrecognized ability to maim fetuses. A few years before that a camel virus — MERS — began infecting and killing people on the Arabian Peninsula. And a few years before that, H1N1 ignited the first flu pandemic in 41 years.
The World Health Organization released its yearly list of infectious diseases that its experts think are especially high-risk. This year’s specimen included the pathogens that public health people consider the usual deadly suspects: Ebola and other hemorrhagic fevers, MERS and SARS, and mosquito-borne Zika and Rift Valley Fever. But there was also a novel entry: Disease X.
Lessons learned from the recent Ebola virus and Zika virus epidemics are that delay in developing the right diagnostic for the right population at the right time has been a costly barrier to disease control and prevention.